JP2024537234A5 - - Google Patents

Info

Publication number
JP2024537234A5
JP2024537234A5 JP2024521130A JP2024521130A JP2024537234A5 JP 2024537234 A5 JP2024537234 A5 JP 2024537234A5 JP 2024521130 A JP2024521130 A JP 2024521130A JP 2024521130 A JP2024521130 A JP 2024521130A JP 2024537234 A5 JP2024537234 A5 JP 2024537234A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
substitution
tgf
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077879 external-priority patent/WO2023064747A1/en
Publication of JP2024537234A publication Critical patent/JP2024537234A/ja
Publication of JP2024537234A5 publication Critical patent/JP2024537234A5/ja
Pending legal-status Critical Current

Links

JP2024521130A 2021-10-11 2022-10-11 操作されたTGF-βモノマーおよび使用法 Pending JP2024537234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11
PCT/US2022/077879 WO2023064747A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Publications (2)

Publication Number Publication Date
JP2024537234A JP2024537234A (ja) 2024-10-10
JP2024537234A5 true JP2024537234A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521130A Pending JP2024537234A (ja) 2021-10-11 2022-10-11 操作されたTGF-βモノマーおよび使用法

Country Status (9)

Country Link
US (1) US20240425559A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416172A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537234A (cg-RX-API-DMAC7.html)
KR (1) KR20240082356A (cg-RX-API-DMAC7.html)
CN (1) CN118103390A (cg-RX-API-DMAC7.html)
AU (1) AU2022367394B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232809A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330579A (cg-RX-API-DMAC7.html)
WO (1) WO2023064747A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
CN116194466A (zh) * 2020-08-27 2023-05-30 联邦高等教育系统匹兹堡大学 编码重组转化生长因子(TGF)-β单体的溶瘤病毒及其用途

Similar Documents

Publication Publication Date Title
EP2576615B1 (en) Fibronectin based scaffold proteins having improved stability
JP2020500511A5 (cg-RX-API-DMAC7.html)
US11952432B2 (en) Cell-permeable stapled peptide modules for cellular delivery
JP4398644B2 (ja) ErbB界面ペプチド擬態およびその使用方法
CN113166220A (zh) 创新细胞因子前药
CN114269366A (zh) 重组fap结合蛋白及其用途
JP2019519528A (ja) 操作されたFcコンストラクトに関する組成物及び方法
JP2023036899A5 (cg-RX-API-DMAC7.html)
ES3011833T3 (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
KR101687060B1 (ko) 모에신 조절제 및 그의 용도
JP2015535523A (ja) アプロチニン由来ポリペプチド−抗体コンジュゲート
AU2017382243A1 (en) Compositions and methods for modulating the immune system
JP2022191261A (ja) 操作されたFcコンストラクトに関する組成物及び方法
JP2021522795A5 (cg-RX-API-DMAC7.html)
JP2025531328A (ja) キメラ抗原受容体t細胞の可逆的制御
CA3242904A1 (en) VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES
EP4559932A1 (en) Multispecific antibody and use thereof
US20230090247A1 (en) Molecules targeting ras protein
US10308917B2 (en) Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
JP2021522793A5 (cg-RX-API-DMAC7.html)
CN116917339A (zh) 靶向dr4和/或dr5的多肽以及相关组合物和方法
JP2022551976A (ja) Peg化キヌレニナーゼ酵素及びがんの治療のためのその使用
US20240360189A1 (en) Dimeric protein complexes and uses thereof
CN111511917A (zh) 肽结合物
CN117295758A (zh) 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白